光線性角化症の世界市場レポート 2025年

光線性角化症市場規模は、今後数年で飛躍的な成長が見込まれます。2029年にはCAGR7.4％で105億8,000万米ドルに成長します。予測期間の成長は、革新的な治療の出現、AIを搭載した診断ツールの進歩、併用治療の採用増加、非侵襲的処置の需要増加、遠隔皮膚科の利用拡大、光線力学的療法の適用拡大、美容的成果に対する意識の高まり、標的生物学的治療の開発、新興国市場でのヘルスケア投資の増加、早期発見と予防への注目の高まりなどに起因すると考えられます。予測期間の主な動向には、AI駆動診断ツール、病変解析のための機械学習、先進光線力学的治療システム、ウェアラブルUVモニタリングデバイス、ナノテクノロジーに基づくドラッグデリバリー、個別化治療のための3Dイメージング、ポータブル家庭用光線療法デバイス、早期発見のためのバイオセンサー、自動病変分類ソフトウェア、ハイドロゲル・ベースの治療システムなどがあります。

重度の日焼けの症例数の増加が、今後の光線性角化症市場の拡大を牽引すると予想されます。重度のサンバーンとは、紫外線（UV）の過剰照射による強い皮膚熱傷のことで、発赤、疼痛、腫脹、時には水疱形成などの症状を引き起こします。このような日焼けは、紫外線に長時間さらされること、日焼け防止対策が不十分であること、紫外線量がピークに達する時間帯に屋外での活動が増えること、気候変動に伴う気温の上昇などの要因によって起こる。日焼けによる紫外線は皮膚細胞のDNAを損傷し、突然変異を引き起こして正常な細胞機能を破壊し、特に繰り返し、あるいは長時間日光にさらされると、前がん病変の形成に寄与します。例えば、2024年5月、英国を拠点とする慈善団体「メラノーマ・フォーカス」は、2022-23年に日焼けが原因で201件の入院があり、その中には89人の子供と25人の1歳未満の乳児が含まれていると報告しました。また、この慈善団体によると、英国の16歳から65歳の成人の66％が子供の頃に日焼けを経験したことを思い出し、65％が少なくとも一度は水ぶくれを伴う重度の日焼けを報告し、この数字は肌の色が薄い、青白い、または白い人の間では77％に増加しました。その結果、重度の日焼けの有病率の上昇が光線性角化症市場の成長に寄与しています。

光線性角化症市場の企業プロファイルは、前がん病変をより効果的に標的として除去し、再発率を低下させ、治療期間の短縮と安全性プロファイルの改善により患者のアドヒアランスを向上させる局所軟膏の開発に注力しています。これらの外用軟膏は、皮膚患部に直接塗布する薬用クリームまたはゲルであり、異常なケラチノサイトを標的として前がん病変を治療するチルバニブリンなどの有効成分を含んでいます。例えば、2024年6月、スペインのバイオ製薬会社Almirall SAは、米国食品医薬品局（FDA）から、同社の医薬品であるKlisyriの使用範囲を100cm2まで拡大するための新薬追加申請（sNDA）の承認を取得しました。Klisyri（tirbanibulin）1％軟膏は、微小管阻害剤で、異常なケラチノサイトの増殖を防ぎ、前がん病変の数と大きさを効果的に減少させるよう設計されており、顔面または頭皮の光線性角化症（AK）の治療に使用されます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界光線性角化症PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の光線性角化症市場：成長率分析
• 世界の光線性角化症市場の実績：規模と成長, 2019-2024
• 世界の光線性角化症市場の予測：規模と成長, 2024-2029, 2034F
• 世界光線性角化症総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の光線性角化症市場治療の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 局所治療
• 外科手術
• 光線力学療法
• その他の治療の種類
• 世界の光線性角化症市場流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• ドラッグストアと薬局
• オンラインプロバイダー
• 世界の光線性角化症市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 皮膚科クリニック
• スパと若返りセンター
• 在宅ケア設定
• その他のエンドユーザー
• 世界の光線性角化症市場、局所治療のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 5-フルオロウラシル（5-FU）
• イミキモド
• ジクロフェナク
• インゲノールメブテート
• レチノイド
• 世界の光線性角化症市場、手術手順のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 凍結療法
• 掻爬術と電気乾燥術
• 切除
• 世界の光線性角化症市場光線力学療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• アミノレブリン酸（ALA）と光療法
• メチルアミノレブリン酸（MAL）と光療法
• 世界の光線性角化症市場、その他の治療タイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• レーザー療法
• ケミカルピーリング
• 併用療法

第7章 地域別・国別分析

• 世界の光線性角化症市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の光線性角化症市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 光線性角化症市場：競合情勢
• 光線性角化症市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Bristol-Myers Squibb
• Novartis AG
• GSK plc
• Amgen Inc.
• Bausch Health Companies Inc.
• Perrigo Company plc
• Galderma SA
• Incyte Corporation
• Leo Pharma Inc.
• Almirall S.A.
• Athenex Inc.
• G&E Herbal Biotechnology Co. Ltd.
• Aclaris Therapeutics Inc.
• Biofrontera Inc.
• Hill Dermaceuticals Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 光線性角化症市場2029：新たな機会を提供する国
• 光線性角化症市場2029：新たな機会を提供するセグメント
• 光線性角化症市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Actinic keratosis (AK), also known as solar keratosis, is a common precancerous skin condition caused by prolonged exposure to ultraviolet (UV) radiation from the sun or artificial sources. It leads to rough, scaly, or crusty patches on sun-exposed areas of the skin, such as the face, scalp, hands, and arms. Actinic keratosis is considered an early stage of squamous cell carcinoma (SCC) and requires treatment to prevent progression. Regular skin checks and protection from sun exposure are important for managing and preventing the development of this condition.

The main types of treatment for actinic keratosis include topical treatments, surgical procedures, photodynamic therapy, and other options. Topical treatment typically involves applying creams or ointments directly to the affected skin areas. Distribution channels for these treatments include hospital pharmacies, drug stores, retail pharmacies, and online providers. End-users of these treatments include hospitals, dermatology clinics, spas and rejuvenation centers, home care settings, and others.

The actinic keratosis market research report is one of a series of new reports from The Business Research Company that provides actinic keratosis market statistics, including actinic keratosis industry global market size, regional shares, competitors with an actinic keratosis market share, detailed actinic keratosis market segments, market trends and opportunities, and any further data you may need to thrive in the actinic keratosis industry. This actinic keratosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The actinic keratosis market size has grown steadily in recent years. It will grow from $7.95 billion in 2024 to $8.44 billion in 2025 at a compound annual growth rate (CAGR) of 6.1%. The growth during the historic period can be attributed to rising UV radiation exposure, an aging population, increasing awareness of skin cancer, a growing prevalence of actinic keratosis, expanding healthcare infrastructure, higher disposable incomes, supportive government initiatives, and a greater focus on preventive skincare.

The actinic keratosis market size is expected to see exponential growth in the next few years. It will grow to $10.58 billion in 2029 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to the emergence of innovative therapies, advancements in AI-powered diagnostic tools, increasing adoption of combination treatments, rising demand for non-invasive procedures, growing use of teledermatology, expanding application of photodynamic therapy, increased awareness of cosmetic outcomes, development of targeted biologic treatments, rising healthcare investment in emerging markets, and a growing focus on early detection and prevention. Major trends in the forecast period include AI-driven diagnostic tools, machine learning for lesion analysis, advanced photodynamic therapy systems, wearable UV monitoring devices, nanotechnology-based drug delivery, 3D imaging for personalized treatments, portable home-based phototherapy devices, biosensors for early detection, automated lesion classification software, and hydrogel-based therapeutic systems.

The growing number of severe sunburn cases is expected to drive the expansion of the actinic keratosis market in the future. Severe sunburns are intense skin burns resulting from excessive exposure to ultraviolet (UV) radiation, which leads to symptoms such as redness, pain, swelling, and occasionally blistering. These sunburns occur due to factors such as prolonged exposure to UV radiation, inadequate sun protection measures, increased outdoor activities during peak UV hours, and rising temperatures linked to climate change. UV radiation from sunburns damages the DNA in skin cells, causing mutations that disrupt normal cell function and contribute to the formation of precancerous lesions, particularly with repeated or extended sun exposure. For example, in May 2024, the UK-based charity Melanoma Focus reported 201 hospital admissions in 2022-23 due to sunburn, including 89 children and 25 infants under one year old. The charity also found that 66% of UK adults aged 16-65 recalled experiencing sunburn as children, with 65% reporting severe sunburn with blisters at least once, a figure that increased to 77% among those with light, pale, or white skin. As a result, the rising prevalence of severe sunburns is contributing to the growth of the actinic keratosis market.

Companies in the actinic keratosis market are focusing on the development of topical ointments that target and eliminate precancerous lesions more effectively, reduce recurrence rates, and improve patient adherence with shorter treatment periods and better safety profiles. These topical ointments are medicated creams or gels applied directly to affected skin areas, containing active ingredients such as tirbanibulin, which works by targeting abnormal keratinocytes to treat precancerous lesions. For instance, in June 2024, Almirall SA, a Spain-based biopharmaceutical company, received approval from the US Food and Drug Administration (FDA) for a supplemental new drug application (sNDA) to extend the use of its drug, Klisyri, to up to 100 cm2. Klisyri (tirbanibulin) 1% ointment is a microtubule inhibitor designed to prevent the proliferation of abnormal keratinocytes, effectively reducing the number and size of precancerous lesions for the treatment of actinic keratosis (AK) on the face or scalp.

In June 2024, Sun Pharmaceutical Industries Limited, an India-based pharmaceutical company, merged with Taro Pharmaceutical Industries Ltd. for $454 million. This merger aims to leverage Taro's expertise in dermatology and pediatrics, as well as its specialty and generic pharmaceuticals and over-the-counter products. Taro Pharmaceutical Industries Ltd, based in Israel, is focused on developing and manufacturing dermatology and topical treatment products, including those for actinic keratosis.

Major players in the actinic keratosis market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb, Novartis AG, GSK plc, Amgen Inc., Bausch Health Companies Inc., Perrigo Company plc, Galderma SA, Incyte Corporation, Leo Pharma Inc., Almirall S.A., Athenex Inc., G&E Herbal Biotechnology Co. Ltd., Aclaris Therapeutics Inc., Biofrontera Inc., Hill Dermaceuticals Inc.

North America was the largest region in the actinic keratosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in actinic keratosis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the actinic keratosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The actinic keratosis market consists of revenues earned by entities by providing services such as skin cancer screenings, cryotherapy, laser treatments, patient education programs and other medical procedures or products for prevention and management. The market value includes the value of related goods sold by the service provider or included within the service offering. The actinic keratosis market also includes sales of cryosurgery devices, laser treatment systems, and sunscreen products. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Actinic Keratosis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on actinic keratosis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for actinic keratosis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The actinic keratosis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment Type: Topical Treatment; Surgical Procedure; Photodynamic Therapy; Other Treatment Types
• 2) By Distribution Channels: Hospital Pharmacies; Drug Stores And Retail Pharmacies; Online Providers
• 3) By End-User: Hospitals; Dermatology Clinics; Spas And Rejuvenation Centers; Homecare Settings; Other End-Users
• Subsegments:
• 1) By Topical Treatment: 5-Fluorouracil (5-FU); Imiquimod; Diclofenac; Ingenol Mebutate; Retinoids
• 2) By Surgical Procedure: Cryotherapy; Curettage And Electrodessication; Excision
• 3) By Photodynamic Therapy: Aminolevulinic Acid (ALA) Plus Light Therapy; Methyl Aminolevulinate (MAL) Plus Light Therapy
• 4) By Other Treatment Types: Laser Therapy; Chemical Peels; Combination Therapies
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche AG; Merck & Co. Inc.; AbbVie Inc.; Sanofi S.A.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Actinic Keratosis Market Characteristics

3. Actinic Keratosis Market Trends And Strategies

4. Actinic Keratosis Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Actinic Keratosis Growth Analysis And Strategic Analysis Framework

• 5.1. Global Actinic Keratosis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Actinic Keratosis Market Growth Rate Analysis
• 5.4. Global Actinic Keratosis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Actinic Keratosis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Actinic Keratosis Total Addressable Market (TAM)

6. Actinic Keratosis Market Segmentation

• 6.1. Global Actinic Keratosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Topical Treatment
• Surgical Procedure
• Photodynamic Therapy
• Other Treatment Types
• 6.2. Global Actinic Keratosis Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Drug Stores And Retail Pharmacies
• Online Providers
• 6.3. Global Actinic Keratosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Dermatology Clinics
• Spas And Rejuvenation Centers
• Homecare Settings
• Other End-Users
• 6.4. Global Actinic Keratosis Market, Sub-Segmentation Of Topical Treatment, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 5-Fluorouracil (5-FU)
• Imiquimod
• Diclofenac
• Ingenol Mebutate
• Retinoids
• 6.5. Global Actinic Keratosis Market, Sub-Segmentation Of Surgical Procedure, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cryotherapy
• Curettage And Electrodessication
• Excision
• 6.6. Global Actinic Keratosis Market, Sub-Segmentation Of Photodynamic Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Aminolevulinic Acid (ALA) Plus Light Therapy
• Methyl Aminolevulinate (MAL) Plus Light Therapy
• 6.7. Global Actinic Keratosis Market, Sub-Segmentation Of Other Treatment Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Laser Therapy
• Chemical Peels
• Combination Therapies

7. Actinic Keratosis Market Regional And Country Analysis

• 7.1. Global Actinic Keratosis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Actinic Keratosis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Actinic Keratosis Market

• 8.1. Asia-Pacific Actinic Keratosis Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Actinic Keratosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Actinic Keratosis Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Actinic Keratosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Actinic Keratosis Market

• 9.1. China Actinic Keratosis Market Overview
• 9.2. China Actinic Keratosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Actinic Keratosis Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Actinic Keratosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Actinic Keratosis Market

• 10.1. India Actinic Keratosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Actinic Keratosis Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Actinic Keratosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Actinic Keratosis Market

• 11.1. Japan Actinic Keratosis Market Overview
• 11.2. Japan Actinic Keratosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Actinic Keratosis Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Actinic Keratosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Actinic Keratosis Market

• 12.1. Australia Actinic Keratosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Actinic Keratosis Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Actinic Keratosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Actinic Keratosis Market

• 13.1. Indonesia Actinic Keratosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Actinic Keratosis Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Actinic Keratosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Actinic Keratosis Market

• 14.1. South Korea Actinic Keratosis Market Overview
• 14.2. South Korea Actinic Keratosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Actinic Keratosis Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Actinic Keratosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Actinic Keratosis Market

• 15.1. Western Europe Actinic Keratosis Market Overview
• 15.2. Western Europe Actinic Keratosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Actinic Keratosis Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Actinic Keratosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Actinic Keratosis Market

• 16.1. UK Actinic Keratosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Actinic Keratosis Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Actinic Keratosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Actinic Keratosis Market

• 17.1. Germany Actinic Keratosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Actinic Keratosis Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Actinic Keratosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Actinic Keratosis Market

• 18.1. France Actinic Keratosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Actinic Keratosis Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Actinic Keratosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Actinic Keratosis Market

• 19.1. Italy Actinic Keratosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Actinic Keratosis Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Actinic Keratosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Actinic Keratosis Market

• 20.1. Spain Actinic Keratosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Actinic Keratosis Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Actinic Keratosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Actinic Keratosis Market

• 21.1. Eastern Europe Actinic Keratosis Market Overview
• 21.2. Eastern Europe Actinic Keratosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Actinic Keratosis Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Actinic Keratosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Actinic Keratosis Market

• 22.1. Russia Actinic Keratosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Actinic Keratosis Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Actinic Keratosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Actinic Keratosis Market

• 23.1. North America Actinic Keratosis Market Overview
• 23.2. North America Actinic Keratosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Actinic Keratosis Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Actinic Keratosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Actinic Keratosis Market

• 24.1. USA Actinic Keratosis Market Overview
• 24.2. USA Actinic Keratosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Actinic Keratosis Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Actinic Keratosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Actinic Keratosis Market

• 25.1. Canada Actinic Keratosis Market Overview
• 25.2. Canada Actinic Keratosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Actinic Keratosis Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Actinic Keratosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Actinic Keratosis Market

• 26.1. South America Actinic Keratosis Market Overview
• 26.2. South America Actinic Keratosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Actinic Keratosis Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Actinic Keratosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Actinic Keratosis Market

• 27.1. Brazil Actinic Keratosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Actinic Keratosis Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Actinic Keratosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Actinic Keratosis Market

• 28.1. Middle East Actinic Keratosis Market Overview
• 28.2. Middle East Actinic Keratosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Actinic Keratosis Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Actinic Keratosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Actinic Keratosis Market

• 29.1. Africa Actinic Keratosis Market Overview
• 29.2. Africa Actinic Keratosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Actinic Keratosis Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Actinic Keratosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Actinic Keratosis Market Competitive Landscape And Company Profiles

• 30.1. Actinic Keratosis Market Competitive Landscape
• 30.2. Actinic Keratosis Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

31. Actinic Keratosis Market Other Major And Innovative Companies

• 31.1. Bristol-Myers Squibb
• 31.2. Novartis AG
• 31.3. GSK plc
• 31.4. Amgen Inc.
• 31.5. Bausch Health Companies Inc.
• 31.6. Perrigo Company plc
• 31.7. Galderma SA
• 31.8. Incyte Corporation
• 31.9. Leo Pharma Inc.
• 31.10. Almirall S.A.
• 31.11. Athenex Inc.
• 31.12. G&E Herbal Biotechnology Co. Ltd.
• 31.13. Aclaris Therapeutics Inc.
• 31.14. Biofrontera Inc.
• 31.15. Hill Dermaceuticals Inc.

32. Global Actinic Keratosis Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Actinic Keratosis Market

34. Recent Developments In The Actinic Keratosis Market

35. Actinic Keratosis Market High Potential Countries, Segments and Strategies

• 35.1 Actinic Keratosis Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Actinic Keratosis Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Actinic Keratosis Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer